Xoma Royalty Corp (XOMA) Stock Price & Analysis
Xoma Royalty Corp (XOMA) rose 0.07% to USD 41.95 as of June 10, 2026 at 05:22 UTC, according to Nexqual real-time market data.
XOMA last closed at USD 41.92; the session ranged USD 41.93–42.31 on volume of 94,844 shares. Market capitalization is $526.10M, with a 52-week range of USD 22.29–42.81 (NGM). Source: Nexqual, June 10, 2026 at 05:22 UTC.
Key Statistics (as of June 10, 2026 at 05:22 UTC)
| Price | USD 41.95 |
|---|---|
| Change | ▲ 0.07% (up) |
| Previous Close | USD 41.92 |
| Open | USD 42.23 |
| Day Range | USD 41.93 – 42.31 |
| 52-Week Range | USD 22.29 – 42.81 |
| Volume | 94,844 shares |
| Market Cap | $526.10M |
| Exchange | NGM |
Technical Analysis (XOMA)
Nexqual's technical model rates XOMA "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 05:22 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 57.74 (neutral) |
| vs SMA50 | Above (USD 39.52) |
| MACD | 0.7 (positive) |
Analyst Ratings (XOMA)
Wall Street analysts rate XOMA "None" based on 1 analysts, with a mean price target of USD 39 (range USD 39–39), per Nexqual as of June 10, 2026 at 05:22 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 39 |
| High Target | USD 39 |
| Low Target | USD 39 |
| Buy / Hold / Sell | 0 / 3 / 0 |
Earnings (XOMA)
| Next Earnings Date | 2026-05-13 |
|---|---|
| Revenue Estimate | $13.91M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD 0.26 vs est -0.13 ▲ beat |
| 2025-09-30 | USD 0.7 vs est -0.04 ▲ beat |
| 2025-06-30 | USD 0.44 vs est -0.15 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:22 UTC.
Financials & Fundamentals (XOMA)
| Total Revenue | $48.55M |
|---|---|
| Revenue Growth (YoY) | -22.60% |
| Gross Margin | +99.04% |
| Operating Margin | -3.90% |
| Profit Margin | +69.63% |
| ROE | +34.23% |
| Debt / Equity | 110.49 |
| Current Ratio | 3.59 |
| Total Cash | $86.09M |
| Total Debt | $124.73M |
| Free Cash Flow | $-13.07M |
Source: Nexqual, June 10, 2026 at 05:22 UTC.
Financial Health Score (XOMA)
Nexqual rates Xoma Royalty Corp's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:22 UTC.
| Growth | Strong — Revenue +83% YoY (annual) |
|---|---|
| Profitability | Weak — Operating margin -4% |
| Balance Sheet | Mixed — $86M cash vs $125M debt |
| Cash Flow | Weak — FCF negative: -$13M, burning cash |
| Efficiency | Strong — ROE 34%, ROA 1.3% |
Ownership (XOMA)
| Insider Ownership | +4.14% |
|---|---|
| Institutional Ownership | +119.90% |
| Shares Outstanding | 12.54M |
| Float | 882,011 |
| Short % of Float | +12.52% |
Source: Nexqual, June 10, 2026 at 05:22 UTC.
Leadership (XOMA)
Xoma Royalty Corp is led by Owen P. Hughes (age 50), CEO & Director, per Nexqual as of June 10, 2026 at 05:22 UTC.
| CEO & Director | Owen P. Hughes (age 50) |
|---|---|
| Chief Financial Officer | Jeffrey Trigilio (age 41) |
Major Backers & Investors (XOMA)
Notable institutional backers of Xoma Royalty Corp include BVF Inc., Morgan Stanley, FMR, LLC, according to Nexqual as of June 10, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| BVF Inc. | 20.65% |
| Morgan Stanley | 16.97% |
| FMR, LLC | 10.39% |
| Fidelity | 8.98% |
| Woodline Partners LP | 5.1% |
| Opaleye Management Inc. | 2.39% |
| GW&K Investment Management, LLC | 1.85% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.65% |
| BlackRock | 7.43% |
| Geode Capital | 1.83% |
Source: Nexqual, June 10, 2026 at 05:22 UTC.
From Xoma Royalty Corp's Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia.
- It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates.
- The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 243.28 | ▲ 2.65% |
| AGEN | Agenus Inc. | USD 3.11 | ▼ 3.72% |
| GERN | Geron Corporation | USD 1.12 | ▼ 4.27% |
| VNDA | Vanda Pharmaceuticals Inc. | USD 6.12 | ▲ 1.49% |
| MYGN | Myriad Genetics, Inc. | USD 4.54 | ▼ 0.66% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:22 UTC. This page is informational and not investment advice.